Cannabis Wheaton Income Corp. Announces A Total Gross of $100 Million | CashCropToday
0 Shares 187 Views

Cannabis Wheaton Income Corp. Announces A Total Gross of $100 Million

February 4, 2018
187 Views

Now, this total gross income comes in based on Wheaton Income Corps. the closing announcement on their disclosed private placement of convertible debenture units. By raising $1,000,000 through a set price of  $1,000 per Convertible Debenture Unit, the whole Million dollar count will go towards the corporate and working capital.

From CEO and Chairman Chuck Rifici Wheaton Income is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Our mandate is to facilitate growth for our partners by providing them with financial support and sharing our collective industry experience. Our partners all have different visions, voices and brand values, and all share a common goal—to build a world-class industry based on ethics, diversity, quality and innovation.

Overall there is a subject 4 month holding period and that’s based under the security issues under the offering.

On the upside, this company statement is seen as a “forward-looking information” approach.

Also the funding will not be limited to Wheaton’s streaming partners. Of course this with certain streaming agreements between general and administrative morale.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
270 views
Market Watch
270 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: